Japanese research for patients with non-metastatic castration resistant prostate cancer - enzalutamide
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 19 Apr 2018
At a glance
- Drugs Enzalutamide (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- Acronyms JCASTRE-Zero
- 17 Apr 2018 Status changed from recruiting to active, no longer recruiting.
- 25 Sep 2017 Planned End Date changed from 1 Sep 2020 to 30 Sep 2021.
- 25 Sep 2017 Planned primary completion date changed from 1 Sep 2020 to 30 Sep 2021.